olaparib,abiraterone,niraparib
gsk,merck,astrazeneca,janssen
['magnitude', 'brca', 'biomarker', 'brcaaway', 'propel']
great slide from summarizing the brcaaway (ph 2), propel (ph 3) and magnitude (ph 3) studies, highlighting each trial s eligibility, biomarker considerations, treatment, and rpfs outcomes (aap vs aap + parp inhibitor) #asco22 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday